^
Association details:
| Biomarker: | BRAF wild-type |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Lenvima (lenvatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of BRAF Variants With Disease Characteristics, Prognosis, and Targeted Therapy Response in Intrahepatic Cholangiocarcinoma
Published date:
03/03/2023
Excerpt:
Patient 2 was a woman in her 60s diagnosed with stage III lCC whose tumor harbored wild-type BRAF. Pharmacologic screens in organoids from this patient (ICC-1) revealed a slight sensitivity to lenvatinib, 8 mg/d, orally. The patient was subsequently treated with gemcitabine with oxaliplatin, PD-1, and lenvatinib for 3 months and achieved a stable disease.
Secondary therapy:
PD1 inhibitor + gemcitabine + oxaliplatin
DOI:
10.1001/jamanetworkopen.2023.1476